Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study.

ABSTRACT: Hepatitis B virus (HBV) infects more than 400 million humans Worldwide. Currently, development of new anti-HBV agents is focused on inhibiting of HBV DNA polymerase activity. The natural components of medicinal plant have a broad spectrum of biological activities with therapeutic properties which can be exploited in various steps of drug discovery. Currently, in silico analyses have been introduced as alternative or supplements methods for drug discovery. This study was planned to in silico screening novel HBV DNA polymerase inhibitor(s) from R. palmatum, R. coreanus and S. officinalis. For this purpose, a set of dominant phytochemicals from mentioned plants were retrieved from PubChem database and primary screening was performed with molecular docking method using iGe

SUBMITTER: Nosrati M 

PROVIDER: S-EPMC6314789 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature